Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Despite the trial's failure, Alector secured a $50 million credit facility from Hercules Capital (NYSE:HTGC) Inc., aimed at supporting ongoing research and development efforts. The company ...
Arnon Rosenthal, the Chief Executive Officer of Alector, Inc. (NASDAQ:ALEC), recently reported the sale of 52,172 shares of the company's common stock, totaling approximately $131,442. The sale ...
As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
A study by the team of Prof. Kristel Sleegers (VIB-UAntwerp), published in Acta Neuropathologica, has offered new insights into the genetic factors that drive Alzheimer’s disease. Using samples from ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
And the first IPO without a fixed share price since the shutdown ended late last month was from Alector, a biotech that is aiming to find new treatments for dementia. Alector fell on its trading ...
The company is also running mid-stage trials of ABBV-552, an SV2A modulator, which is being evaluated to enhance synaptic efficiency in Alzheimer's, and Alector-partnered TREM2-directed antibody ...